8-K: Current report filing
Published on October 17, 2023
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported):
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of principal executive offices)
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act of 1933 (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(e) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol(s) | Name of each exchange on which registered | ||
| The
|
||||
| The
|
| Item 1.01 | Entry into a Material Definitive Agreement. |
Amendment to Development Collaboration Agreement
On October 8, 2021, Lixte Biotechnology Holdings, Inc. (the “Company”) entered into a Development Collaboration Agreement (the “Collaboration Agreement”) with the Netherlands Cancer Institute, Amsterdam (NKI), one of the world’s leading comprehensive cancer centers, and Oncode Institute, Utrecht, a major independent cancer research center, to identify the most promising drugs to be combined with LB-100, and potentially LB-100 analogues, to be used to treat a range of cancers, as well as to identify the specific molecular mechanisms underlying the identified combinations. On October 13, 2023, the parties signed an amendment (“Amendment 2”) to expand the collaboration to study drug synergies of the Company’s lead compound, LB-100, with immunotherapy in various cancers. Under Amendment 2, the parties will seek to find synthetic lethal combinations in additional cancer types. Amendment 2 also extends the Collaboration Agreement for an additional two years. The foregoing description of Amendment 2 does not purport to be complete and is subject to and qualified in its entirety by the full text of Amendment 2, a copy of which is filed hereto as Exhibit 10.1.
| Item 8.01 | Other Events. |
On October 16, 2023, the Company issued a press release with respect to Amendment 2 of the Development Collaboration Agreement.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits |
Filed as part of this Current Report on Form 8-K are the exhibits listed on the accompanying Index to Exhibits, which information is incorporated herein by reference.
| -2- |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: October 17, 2023 | LIXTE BIOTECHNOLOGY HOLDINGS, INC. | |
| By: | /s/ BASTIAAN VAN DER BAAN | |
|
Bastiaan van der Baan, President and Chief Executive Officer |
||
| -3- |
INDEX TO EXHIBITS
| Exhibit No. | Description | |
| 10.1 | Amendment 2 to Development Collaboration Agreement (certain portions of this Exhibit have been omitted) | |
| 99.1 | Press Release Announcing the Amendment to the Development Collaboration Agreement | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL Document) |
| -4- |